Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression

NCT01324934 is registered in ClinicalTrials.gov with Neovii Biotech as lead sponsor.

NCT NCT01324934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01324934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression
Lead sponsor
Neovii Biotech
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2006
Completion date
January 31, 2011
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

renal transplant rejection